Production (Stage)
Tonix Pharmaceuticals Holding Corp.
TNXP
$28.93
$2.539.58%
NASDAQ
| 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | |
|---|---|---|---|---|---|
| Revenue | 2.43M | 2.58M | 2.82M | 2.21M | 2.48M |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 2.43M | 2.58M | 2.82M | 2.21M | 2.48M |
| Cost of Revenue | 943.00K | 1.18M | 1.56M | 3.37M | 1.66M |
| Gross Profit | 1.49M | 1.40M | 1.27M | -1.16M | 822.00K |
| SG&A Expenses | 10.10M | 15.58M | 7.71M | 7.50M | 9.31M |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 18.48M | 25.06M | 18.38M | 20.57M | 23.83M |
| Operating Income | -16.05M | -22.48M | -15.55M | -18.36M | -21.35M |
| Income Before Tax | -16.83M | -22.11M | -14.21M | -78.78M | -14.94M |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -16.83M | -22.11M | -14.21M | -78.78M | -14.94M |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -16.83M | -22.11M | -14.21M | -78.78M | -14.94M |
| EBIT | -16.05M | -22.48M | -15.55M | -18.36M | -21.35M |
| EBITDA | -15.56M | -21.51M | -15.04M | -17.39M | -20.34M |
| EPS Basic | -2.84 | -9.77 | -22.88 | -1.93K | -535.72 |
| Normalized Basic EPS | -1.55 | -6.10 | -14.30 | -303.22 | -334.82 |
| EPS Diluted | -2.84 | -9.77 | -22.88 | -1.93K | -535.72 |
| Normalized Diluted EPS | -1.55 | -6.10 | -14.30 | -303.22 | -334.82 |
| Average Basic Shares Outstanding | 5.93M | 2.26M | 621.20K | 40.90K | 27.90K |
| Average Diluted Shares Outstanding | 5.93M | 2.26M | 621.20K | 40.90K | 27.90K |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |